Feb 15,2018

Reduced Time in Hypoglycemia Demonstrated in Tandem Diabetes Care's Pivotal Trial for the t:slim X2 Insulin Pump with Predictive Low Glucose Suspend Feature; Data to be Presented at ATTD 2018 Conference

Tandem Diabetes Care®, Inc., a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced positive results from a pivotal study of the t:slim X2™ Insulin Pump with Basal-IQ technology, a predictive low glucose suspend (PLGS) feature. Data showed that the system achieved the primary outcome of reducing time spent in hypoglycemia compared to sensor-augmented pump therapy alone.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 15,2018

DreaMed Diabetes Receives CE Mark for Platform for the Management of Type 1 Diabetes

DreaMed Diabetes, developer of diabetes management solutions, announced today that it received CE Mark for the Advisor Pro decision-support platform for assisting healthcare professionals in the management of Type 1 diabetes.

REGULATORY CE MARK
View Analyst & Ambassador Comments
Go to original news
Feb 15,2018

New Pediatric At-Home Study of MiniMed(TM) 670G System Demonstrates Positive Results in Children Ages 7 to 13

Medtronic plc, the global leader in medical technology, today announced that new data from its at-home pediatric study of the MiniMed(TM) 670G system in patients 7-13 years of age were presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 11th International Conference in Vienna, Austria.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 20,2018

Wellthy Therapeutics Presents Groundbreaking Results at the World's Largest Diabetes Technology Conference

Digital therapeutics leader Wellthy Therapeutics shared interim results of an ongoing real-world pilot to evaluate the effectiveness of the Wellthy Diabetes Smartphone App, becoming the first company in South Asia to do so. The results were shared via an oral presentation and a scientific poster presented at the 11th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2018).

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 20,2018

Tandem Diabetes Care Applies for Health Canada Medical Device License

Tandem Diabetes Care®, Inc., a medical device company and manufacturer of the only touchscreen insulin pumps, today announced its submission of a medical device license application to Health Canada to market its t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose monitoring (CGM) integration. The Company plans to launch the pump in Canada in the second half of 2018, subject to regulatory approvals.

PRODUCT

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 21,2018

Medtronic Introduces MiniMed(TM) Mio(TM) Advance Infusion Set for People with Diabetes

Medtronic plc, the global leader in medical technology, services and solutions, today introduced the MiniMed Mio Advance infusion set. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed portfolio of infusion sets and gives patients a simpler, faster and more convenient set change with fewer steps. The new infusion set will first be available in select countries around the world with plans to expand availability over time.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 21,2018

Insulet Reports Fourth Quarter Revenue of $130.5 Million, Up 26%, and Gross Margin Up 210 Basis Points, Exceeding Expectations

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months and full year ended December 31, 2017.

View Analyst & Ambassador Comments
Go to original news
Feb 26,2018

Medtronic Receives FDA Approval for New Arm Indication for Guardian(TM) Sensor 3 - Further Enhancing the MiniMed(TM) 670G Hybrid Closed Loop Experience

Medtronic plc, the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved a new arm indication for the Guardian Sensor 3. This expanded indication will enable patients to wear the sensor on the upper arm - delivering more flexibility and enhanced performance for users, as well as improved accuracy, with a MARD of 8.7 percent following typical calibration methods used with the MiniMed 670G system.

REGULATORY FDA

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 27,2018

A Novel Approach for Fully Automated, Personalized Health Coaching for Adults with Prediabetes: Pilot Clinical Trial

Prediabetes is a high-risk state for the future development of type 2 diabetes, which may be prevented through physical activity (PA), adherence to a healthy diet, and weight loss. Mobile health (mHealth) technology is a practical and cost-effective method of delivering diabetes prevention programs in a real-world setting. Sweetch (Sweetch Health, Ltd) is a fully automated, personalized mHealth platform designed to promote adherence to PA and weight reduction in people with prediabetes.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 28,2018

Insulet Corporation to Present at Upcoming Investor Conferences

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at three upcoming investor conferences.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES